Acutaas Chemicals share price
NSE: ACUTAASBSE: 543349Pharmaceuticals & BiotechnologySmall Cap
Acutaas Chemicals Limited · Formerly Ami Organics · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 2021 · Issue price ₹610
Last close ₹3,793.30up ₹444.50 (13.27%)BSE ₹3,794.55
Share price at the NSE close on 27 Oct 2026. Previous close ₹3,348.80.
27 Oct: open ₹3,365.00, high ₹3,900.00, low ₹3,360.50
52-week range of traded prices to 27 Oct 2026
₹1,570.00Low, 21 Jan 2026₹3,900.00High, 27 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹31,056 Cr347th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 70.72
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 16.72
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.07%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 26.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 47,46,62021.2% delivered
About Acutaas Chemicals
Acutaas Chemicals Limited is a specialty chemicals company with its registered office at GIDC Sachin, Surat, in Gujarat. It runs four business verticals: advanced pharmaceutical intermediates, semiconductor chemicals, battery chemicals and commodity chemicals. It began in 2004 as a partnership firm and was incorporated in 2007.
The pharmaceutical intermediates business started by supporting an innovator molecule and then expanded into generic pharmaceutical intermediates. It also works with customers as a contract manufacturer and developer (CMO/CDMO). Semiconductor chemicals come from Baba Fine Chemicals in Greater Noida, Uttar Pradesh, a partnership firm in which the company holds 55% of the partnership rights. It makes photoresist chemicals. The battery chemicals vertical makes the electrolyte additives Vinylene Carbonate and Fluoroethylene Carbonate at Jhagadia, where the first phase was inaugurated on 19 January 2026.
Manufacturing sites are at Sachin, Ankleshwar and Jhagadia in Gujarat, and at Greater Noida. A fifth site is under construction at Gongju in South Korea. It belongs to Indichem Inc., a joint venture with South Korea's J & Materials Co. Ltd., in which the company's wholly owned subsidiary Acutaas Advance Material Limited holds 75%. The company has more than 1,000 employees and a research team of more than 130 people.
It acquired the Ankleshwar and Jhagadia units from Gujarat Organics Ltd. in 2021, and Baba Fine Chemicals in 2023, which marked its entry into semiconductor chemicals. Its founder, Naresh Patel, is its chairman and managing director.
Written from the annual report for the year to Mar 2026, filed 29 Aug 2026 and the investor presentation.
Sources for 28 statements, each with its page
- Registered office is at GIDC Sachin, Surat, Gujarat. Annual report, page 1
- Registered office district Surat, Gujarat. Annual report, page 1
- Four business verticals: pharmaceutical intermediates, semiconductor chemicals, battery chemicals, commodity chemicals. Annual report, page 5
- Advanced pharmaceutical intermediates is one vertical. Annual report, page 5
- Began in 2004 as a partnership firm. Annual report, page 7
- Incorporated in 2007 (year in CIN). Annual report, page 1
- Pharma intermediates began by supporting an innovator molecule. Annual report, page 9
- then expanded into generic pharmaceutical intermediates. Annual report, page 9
- Works with customers through its CMO/CDMO business. Annual report, page 9
- Baba Fine Chemicals is in Greater Noida, UP. Annual report, page 6
- Baba Fine Chemicals is a partnership firm in which the company has 55% partnership rights. Annual report, page 70
- Baba Fine Chemicals is a partnership firm. Annual report, page 70
- Makes photoresist chemicals. Annual report, page 16
- Battery chemicals vertical makes electrolyte additives VC and FEC. Annual report, page 16
- Jhagadia battery chemicals plant Phase 1 inaugurated on 19 January 2026. Annual report, page 16
- Inauguration date 19 January 2026. Annual report, page 16
- Plants at Sachin, Ankleshwar, Jhagadia (Gujarat). Annual report, page 6
- Fifth manufacturing facility under construction in South Korea. Annual report, page 6
- Facility at Gongju, South Korea belongs to Indichem Inc. JV. Annual report, page 6
- Indichem is a joint venture with South Korea's J & Materials Co. Ltd. Annual report, page 7
- Indichem Inc. is a joint venture. Annual report, page 7
- Acutaas Advance Material Limited is a wholly owned subsidiary holding 75% of Indichem. Annual report, page 70
- Employees: more than 1,000. Annual report, page 12
- R&D team size more than 130. Annual report, page 12
- Acquired Ankleshwar and Jhagadia units in 2021. Annual report, page 7
- Units acquired from Gujarat Organics Ltd. Annual report, page 7
- Acquired Baba Fine Chemicals in 2023, entry into semiconductor. Annual report, page 7
- Founder is Naresh Patel, chairman and managing director. Annual report, page 7
Results
Consolidated; ₹ crore.Acutaas Chemicals quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +45.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +96.1%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹437 Crup 32.53%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹123 Crup 64.21%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 28.2%
Revenue by quarter
Peak revenue ₹437 Cr, quarter to Sep 2026; lowest ₹207 Cr, quarter to Jun 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 275 | 308 | 207 | 306 | 393 | 433 | 330 | 437 |
| Net profit | 45 | 63 | 44 | 72 | 106 | 134 | 75 | 123 |
| Net margin | 16.5% | 20.3% | 21.2% | 23.5% | 27.0% | 31.0% | 22.7% | 28.2% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,339 Crup 33.02%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹356 Crup 122.15%
- Net margin
- 26.6%
Revenue by year
Peak revenue ₹1,339 Cr, year to Mar 2026; lowest ₹520 Cr, year to Mar 2022
Net profit by year, a loss in red
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 520 | 617 | 717 | 1,007 | 1,339 |
| Net profit | 72 | 83 | 49 | 160 | 356 |
| Net margin | 13.8% | 13.5% | 6.8% | 15.9% | 26.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Custom synthesis and manufacturing of Speciality Chemicals having application in Pharmaceuticals API and others, which carries all its revenue.
Valuation
Today, against the company's own history.Acutaas Chemicals PE ratio and valuation
Price to earnings
At or below today's level on 77% of 1,101 trading days since May 2022.
LowestHighest
Its median59.13Industry median28.32
Price to book
At or below today's level on 98% of 1,149 trading days over the last 5 years.
LowestHighest
Its median7.34Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 26% of 1,202 trading days over the last 5 years.
LowestHighest
Its median0.14%Industry median0.50%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +109.8% | +124.5% | −6.6% | 0.1% |
| 3 years | +79.3% | +56.1% | +14.7% | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual fund holdings
164 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 67 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 164 funds holding Acutaas Chemicals
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 8
- AddedAdded. Funds that held more shares than at the end of the month before.
- 50
- CutCut. Funds that held fewer shares than at the end of the month before.
- 43
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 62
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal Flexi cap FundMotilal Oswal Mutual Fund | 10,86,350 | 2.65% | ₹356.3 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 9,00,000 | 5.03% | ₹295.1 Cr |
 Kotak Multi Cap FundKotak Mahindra Mutual Fund | 8,26,974 | 0.89% | ₹271.2 Cr |
| Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 4,53,378 | 0.98% | ₹148.7 Cr |
 UTI Small Cap FundUTI Mutual Fund | 4,01,249 | 2.52% | ₹131.6 Cr |
 ITI Small Cap FundITI Mutual Fund | 3,96,614 | 3.55% | ₹130.1 Cr |
| Kotak Balanced Advantage FundKotak Mahindra Mutual Fund | 3,86,016 | 0.76% | ₹126.6 Cr |
| SBI Small Cap FundSBI Mutual Fund | 3,71,566 | 0.30% | ₹121.9 Cr |
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 3,39,010 | 3.18% | ₹111.2 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 3,37,693 | 0.59% | ₹110.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Acutaas Chemicals insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Directors and key managers1 purchase, 2 sales₹0.04 Cr₹16 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹16 Cr
- Employees1 purchase, 2 sales₹0.35 Cr₹4.33 CrNet−₹3.98 Cr
- Others: no market trade · 1 pledge created
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Acutaas Chemicals competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Acutaas Chemicals in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Ajanta PharmaAJANTPHARM | 41,906 | 36.93 | 9.26 | +20.2% | +22.0% | 27.3% | 27.2% | 1.79% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 41,884 | 39.21 | 18.47 | +5.8% | +12.4% | 50.6% | 56.3% | 2.31% |
 Emcure PharmaceuticalsEMCURE | 35,575 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,570 | 87.27 | 12.71 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 30,627 | 74.88 | 6.20 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Piramal PharmaPPLPHARMA | 26,457 | – | 3.25 | +9.4% | – | −2.6% | 2.3% | 0.00% |
 Rubicon ResearchRUBICON | 24,989 | 86.70 | 19.39 | – | – | 22.4% | 25.8% | 0.10% |
 Neuland LaboratoriesNEULANDLAB | 24,781 | 49.78 | 13.22 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Acutaas Chemicals dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹2.50 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 17 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹2.50 |
| 18 Sep 2025 | Final | ₹1.50 |
| 13 Sep 2024 | Final | ₹3.00 |
| 18 Sep 2023 | Final | ₹3.00 |
| 29 Jul 2022 | Final | ₹3.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Acutaas Chemicals announcements
Oct 2026
27 Oct · Business
27 Oct · Results
22 Oct · Analysts
22 Oct · Board meeting
17 Oct · Business
Sep 2026
26 Sep · Management
Acutaas Chemicals share price by year
Each calendar year to 2025.Acutaas Chemicals share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,704.90 | +58.7% | 1,872.20 | 940.93 |
| 2024 | 1,074.43 | +91.5% | 1,149.68 | 509.98 |
| 2023 | 561.00 | +16.2% | 684.93 | 432.85 |
| 2022 | 482.68 | −9.6% | 577.10 | 403.33 |
| 2021 | 534.20 | – | 697.15 | 433.95 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 14 Sep 2021.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 3,136.20 | 3,364.80 | 3,136.20 | 3,348.80 | 3,304.79 | 12,44,552 | 52.3% |
| 23 Oct 2026 | 3,219.40 | 3,236.70 | 3,085.00 | 3,137.70 | 3,126.62 | 3,48,109 | 55.1% |
| 22 Oct 2026 | 3,152.10 | 3,253.00 | 3,130.60 | 3,215.30 | 3,208.59 | 3,09,343 | 52.9% |
| 21 Oct 2026 | 3,262.90 | 3,269.80 | 3,100.00 | 3,152.40 | 3,170.86 | 3,04,749 | 48.1% |
| 19 Oct 2026 | 3,275.00 | 3,354.40 | 3,234.10 | 3,253.40 | 3,298.70 | 5,57,451 | 30.5% |
| 16 Oct 2026 | 3,132.50 | 3,219.00 | 3,116.60 | 3,206.00 | 3,180.50 | 4,82,617 | 45.2% |
| 15 Oct 2026 | 3,179.00 | 3,192.00 | 3,125.10 | 3,132.50 | 3,152.16 | 2,11,008 | 54.9% |
| 14 Oct 2026 | 3,176.90 | 3,203.50 | 3,115.10 | 3,160.50 | 3,163.78 | 3,47,396 | 51.9% |
| 13 Oct 2026 | 3,160.00 | 3,206.00 | 3,062.40 | 3,176.70 | 3,117.28 | 2,52,189 | 49.7% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Apr 2025 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- ACUTAAS
- BSE code
- 543349
- ISIN
- INE00FF01025
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- AMIORG
- Website
- www.amiorganics.com
- CIN
- L24100GJ2007PLC051093
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2007
- Registered office
- Plot No. 440/4, 5 & 6, G.I.D.C, Sachin, Road No. 82/A, Surat 394230, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap